Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
MarketBeat on MSN1d
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialDetailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
GlobalData on MSN3d
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...
Hosted on MSN1d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback